The US Giant Gilead is opening a new program of Grants to fund the next generation of HIV research for 3-years. Targets are academic institutions and non-profit organization.
HIV remains a global health challenge, with around 37 million people infected in the world. The rate of new infections fell in the last decades, but it is still estimated that 2 million people become newly infected. Without a cure, these numbers just keep piling up.
HIV treatment consists of antiretroviral therapy (ART), which manages the multiplication of the virus and blocks the progression of the disease – especially after developing into AIDS, which kills about 1.2 million people annually.
Within this scenario, there is still more than enough demand for new HIV therapy research – and consequently many Pharma companies and Biotechs are investing it.